Back
Compare AU
Compare EMKT vs. DRUG
Compare shares and ETFs on the ASX that you can trade on Pearler.
Overview
When it comes to investing in the Australian stock market, Exchange-Traded Funds (ETFs) are a popular choice. Two well-known options in the Australian Securities Exchange (ASX) are the VanEck MSCI Multifactor Em Markets Equity ETF (EMKT) and the Betashares Global Healthcare Currency Hedged ETF (DRUG). In this comparison, we'll delve into these ETFs across various dimensions to help you make an informed investment decision.
Community Stats
EMKT | DRUG | |
|---|---|---|
Popularity | Low | Low |
Pearlers invested | 316 | 74 |
Median incremental investment | $1,206.83 | $740.50 |
Median investment frequency | Monthly | Monthly |
Median total investment | $4,999.28 | $1,964.60 |
Average age group | > 35 | 26 - 35 |
Key Summary
EMKT | DRUG | |
|---|---|---|
Strategy | EMKT.AX was created on 2018-04-10 by VanEck. The fund's investment portfolio concentrates primarily on total market equity. The VanEck MSCI Multifactor Emerging Markets Equity ETF (EMKT.AX) invests in a diversified portfolio of emerging markets listed securities with the aim of providing investment returns, before fees and other costs, which track the performance of the MSCI Emerging Markets Diversified MultipleFactor Index (AUD) (EMKT.AX Index). | DRUG.AX was created on 2016-08-04 by BetaShares. The fund's investment portfolio concentrates primarily on health care equity. DRUG.AX aims to track the performance of an index (before fees and expenses) that comprises the largest global healthcare companies (ex-Australia), hedged into Australian dollars. |
Top 3 holdings | Taiwan Semiconductor Manufacturing Co Ltd (10.04 %) SK Hynix Inc (4.92 %) SK Square (3.18 %) | BRL - BRAZILIAN REAL (0 %) AUD - AUSTRALIA DOLLAR (0 %) CHF - SWISS FRANC (0 %) |
Top 3 industries | Information Technology (48.20 %) Consumer Discretionary (13.91 %) Financials (12.98 %) | Other (75.91 %) Communication Services (33.53 %) Health Care (23.80 %) |
Top 3 countries | China (26.35 %) Taiwan (20.98 %) Korea (20.42 %) | United States (69.91 %) Switzerland (10.93 %) United Kingdom of Great Britain and Northern Ireland (7.38 %) |
Management fee | 0.69 % | 0.57 % |
Key Summary
EMKT | DRUG | |
|---|---|---|
Issuer | VanEck | BetaShares |
Tracking index | MSCI Emerging Markets Diversified Multiple-Factor Index - AUD | Nasdaq Global ex-Australia Healthcare Hedged AUD Index - AUD |
Asset class | ETF | ETF |
Management fee | 0.69 % | 0.57 % |
Price | $33.44 | $8.93 |
Size | $532.778 million | $182.424 million |
10Y return | N/A | N/A |
Annual distribution yield (5Y) | 3.42 % | 1.92 % |
Market | ASX | ASX |
First listed date | 12/04/2018 | 08/08/2016 |
Purchase fee | $6.50 | $6.50 |
Community Stats
EMKT | DRUG | |
|---|---|---|
Popularity | Low | Low |
Pearlers invested | 316 | 74 |
Median incremental investment | $1,206.83 | $740.50 |
Median investment frequency | Monthly | Monthly |
Median total investment | $4,999.28 | $1,964.60 |
Average age group | > 35 | 26 - 35 |
Pros and Cons
EMKT | DRUG | |
|---|---|---|
Pros |
|
|
Cons |
|
|
EMKT | DRUG |
|---|---|
Lower exposure to US market | Higher exposure to US market |
Higher management fee | Lower management fee |
Higher price growth | Lower price growth |
Higher distribution yield | Lower distribution yield |